Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6%
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Frontage Holdings Corp
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Cash from Financing Activities
$12.9m
CAGR 3-Years
N/A
CAGR 5-Years
58%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Financing Activities
-$4.6B
CAGR 3-Years
-33%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Cash from Financing Activities
-$8.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-34%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Financing Activities
-$881.3m
CAGR 3-Years
-13%
CAGR 5-Years
-12%
CAGR 10-Years
-13%
Agilent Technologies Inc
NYSE:A
Cash from Financing Activities
-$978m
CAGR 3-Years
-15%
CAGR 5-Years
-1%
CAGR 10-Years
-4%
IQVIA Holdings Inc
NYSE:IQV
Cash from Financing Activities
-$923m
CAGR 3-Years
11%
CAGR 5-Years
-59%
CAGR 10-Years
-18%
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Cash from Financing Activities?
Cash from Financing Activities
12.9m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Cash from Financing Activities amounts to 12.9m USD.

What is Frontage Holdings Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
58%

Over the last year, the Cash from Financing Activities growth was -58%.

Back to Top